diABZI-4 is a diamidobenzimidazole STING agonist, induces oligomerization of STING and activates STING and is highly effective in limiting SARS-CoV-2 replication.
diABZI-4 has a more favorable solubility profile for in vivo studies in comparison to the previously reported diABZI-3 (Cat#PC-35785, STING agonist diABZI compound 3
).
diABZI-4 induces oligomerization of STING, transcription of IFNB1, CXCL10, TNF and IL6 and the secretion of IFN-β and TNF-α in primary human CD14+ monocytes.
diABZI-4 induces oligomerization of STING , phosphorylation of IRF3, TBK1, p65 and autophagy (LC3 conversion) in bone marrow derived macrophages (BMDMs), also induces the expression and secretion of IFN-β, CXCL10, TNF-α and IL-6.
diABZI-4 inhibits SARS-CoV-2 gene expression and replication in infected lung epithelial cells.
diABZI-4 (0.5mg/kg) protects against SARS-CoV-2 infection in hACE2 transgenic mice, promotes myeloid and lymphocyte activation in the lung.
diABZI-4 protects against SARS-CoV-2 infection through IFN-dependent and -independent mechanisms.